Natural products modulating the hERG channel: heartaches and hope

Jadel M Kratz1, Ulrike Grienke, Olaf Scheel

  • 1Department of Pharmacognosy, Faculty of Life Sciences, University of Vienna, Althanstraße 14, 1090 Vienna, Austria. judith.rollinger@univie.ac.at.

Insights

The human Ether-à-go-go Related Gene (hERG) channel is crucial for heart function. This review compiles data on natural compounds that block the hERG channel, impacting cardiac safety and drug development.

Area of Science:

  • Cardiovascular Pharmacology
  • Ion Channel Physiology
  • Natural Product Chemistry

Background:

  • The human Ether-à-go-go Related Gene (hERG) channel is vital for cardiac electrical activity, regulating repolarization.
  • hERG channel dysfunction, due to gene mutations or small molecule blockage, increases the risk of fatal cardiac arrhythmias.
  • hERG channel blockers have led to drug withdrawals, highlighting its importance as an antitarget in drug discovery.

Purpose of the Study:

  • To critically compile hERG channel data for natural products and extracts from 1996-2016.
  • To provide a molecular understanding of hERG channel functions and their clinical relevance.
  • To explore strategies for identifying hERG channel blockers from natural sources and their implications for cardiac safety.

Main Methods:

  • Comprehensive literature review of studies published between 1996 and 2016.
  • Compilation and critical analysis of hERG channel blocking data for isolated natural products and botanical extracts.
  • Assessment of the translational potential of in vitro/in vivo findings to human cardiotoxicity.

Main Results:

  • Identified a significant body of research on hERG channel interactions with natural compounds over two decades.
  • Highlighted the lack of routine assessment for hERG channel blocking profiles of commonly consumed botanicals.
  • Detailed the known cardiotoxic risks associated with hERG channel modulation by natural products.

Conclusions:

  • Natural compounds in dietary supplements and herbal products can interact with the hERG channel, posing potential cardiac risks.
  • There is a need for systematic evaluation of hERG channel activity in phytopharmaceuticals and dietary supplements.
  • Future research should focus on developing cardiac safety guidelines and exploring novel therapeutic applications of hERG channel modulation.

Related Concept Videos

G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
6.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.8K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.7K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.4K